As Crohn’s disease falls under the umbrella of inflammatory bowel disease, the prevalence is murky, but estimates suggest it may affect 1 million Americans.
The calprotectin biomarker test stands at the crossroads to help direct physicians and patients to appropriate focused care for gut and brain symptoms.